NASDAQ:ARVN - Arvinas Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $129.23
Forecasted Upside: 35.36 %
Number of Analysts: 13
Breakdown:
0 Sell Ratings
0 Hold Ratings
13 Buy Ratings
0 Strong Buy Ratings

^$95.47 As of 07/23/2021 01:00 AM ET

▲ +10.96 (12.97%)

1 month | 3 months | 12 months

Get New Arvinas Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

^$129.23

▲ +35.36% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $129.23, with a high forecast of $170.00 and a low forecast of $93.00. The average price target represents a 35.36% upside from the last price of $95.47.

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/30/2020

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/29/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/28/2020

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/26/2020

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/24/2021

0 strong buy ratings
12 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/24/2021

0 strong buy ratings
12 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/23/2021

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/23/2021	BMO Capital Markets	Boost Price Target	Outperform	$101.00 ➝ $111.00	High
7/23/2021	Citigroup	Boost Price Target	Buy	$118.00 ➝ $153.00	High
7/23/2021	HC Wainwright	Reiterated Rating	Buy	$100.00 ➝ $135.00	High
7/23/2021	Oppenheimer	Boost Price Target	Outperform	$100.00 ➝ $108.00	High
7/22/2021	Piper Sandler	Reiterated Rating	Overweight	$97.00 ➝ $105.00	High
7/22/2021	Truist	Boost Price Target	Buy	$150.00 ➝ $170.00	High
7/22/2021	Truist Securities	Boost Price Target	Buy	$150.00 ➝ $170.00	High
5/20/2021	UBS Group	Initiated Coverage	Buy	$123.00	High
4/21/2021	Northern Trust Capital Markets	Initiated Coverage	Buy		Low
4/21/2021	Truist Securities	Initiated Coverage	Buy	$150.00	High
4/21/2021	Truist	Initiated Coverage	Buy	$150.00	High
3/31/2021	BMO Capital Markets	Initiated Coverage	Outperform	$101.00	High
3/30/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$121.00 ➝ $140.00	High
1/19/2021	Oppenheimer	Boost Price Target		$80.00 ➝ $100.00	Low
1/5/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$66.00 ➝ $121.00	N/A
12/21/2020	Piper Sandler	Boost Price Target	Overweight	$58.00 ➝ $97.00	Low
12/15/2020	Smith Barney Citigroup	Boost Price Target		$43.00 ➝ $123.00	High
12/15/2020	Roth Capital	Boost Price Target	Buy	$65.00 ➝ $120.00	High
12/14/2020	HC Wainwright	Reiterated Rating	Buy	$60.00 ➝ $100.00	High
12/14/2020	BMO Capital Markets	Boost Price Target	Outperform	$62.00 ➝ $114.00	High
12/14/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High
12/14/2020	The Goldman Sachs Group	Boost Price Target	Buy	$78.00 ➝ $129.00	High
12/14/2020	Wedbush	Boost Price Target	Outperform	$62.00 ➝ $93.00	High
12/1/2020	Cantor Fitzgerald	Lower Price Target		$75.00 ➝ $66.00	Medium
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		High
10/8/2020	Oppenheimer	Reiterated Rating	Hold		High
8/4/2020	Oppenheimer	Initiated Coverage	Hold		Low
6/1/2020	Citigroup	Upgrade	Neutral ➝ Buy	$45.00	Medium
5/31/2020	Oppenheimer	Initiated Coverage	Hold		Low
5/29/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
5/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Medium
5/11/2020	Oppenheimer	Initiated Coverage	Market Perform		Medium
5/4/2020	Roth Capital	Boost Price Target	Buy	$35.00 ➝ $65.00	High
4/29/2020	HC Wainwright	Reiterated Rating	Buy	$50.00 ➝ $60.00	Medium
4/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
3/16/2020	Piper Sandler	Reiterated Rating	Buy	$58.00	High
1/30/2020	BMO Capital Markets	Reiterated Rating	Outperform	$62.00	High
1/24/2020	Wedbush	Boost Price Target	Outperform	$39.00 ➝ $60.00	Medium
1/6/2020	Piper Jaffray Companies	Boost Price Target	Overweight	$35.00 ➝ $58.00	N/A
12/20/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$42.00 ➝ $75.00	Low
12/19/2019	HC Wainwright	Initiated Coverage	Buy	$50.00	High
11/25/2019	Guggenheim	Initiated Coverage	Buy	$50.00	High
11/14/2019	Roth Capital	Initiated Coverage	Buy	$35.00	Medium
11/13/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$32.00 ➝ $35.00	High
10/24/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$23.00 ➝ $38.00	Medium
9/24/2019	Wedbush	Initiated Coverage	Outperform	$35.00 ➝ $38.00	Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$34.00	High
8/5/2019	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$42.00 ➝ $42.00	Medium
6/5/2019	Citigroup	Downgrade	Buy ➝ Neutral	$21.00 ➝ $22.00	High
5/8/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$23.00 ➝ $32.00	High
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		High
10/22/2018	Citigroup	Initiated Coverage	Buy ➝ Buy	$21.00	Low
10/22/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.00	High
10/22/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$23.00	High

(Data available from 7/24/2016 forward)

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $95.47

$85.57

$96.78

50 Day Range

MA: $75.83

$63.79

$95.47

52 Week Range

Now: $95.47

$19.68

$96.78

Volume

1,665,656 shs

Average Volume

466,353 shs

Market Capitalization

$4.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

The following Wall Street research analysts have issued reports on Arvinas in the last year: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Northern Trust Capital Markets, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, Smith Barney Citigroup, The Goldman Sachs Group, Inc., Truist, Truist Securities, UBS Group AG, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ARVN.

What is the current price target for Arvinas?

13 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $129.23, suggesting a possible upside of 35.4%. Truist has the highest price target set, predicting ARVN will reach $170.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $93.00 for Arvinas in the next year.
View the latest price targets for ARVN.

What is the current consensus analyst rating for Arvinas?

Arvinas currently has 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARVN will outperform the market and that investors should add to their positions of Arvinas.
View the latest ratings for ARVN.

What other companies compete with Arvinas?

Other companies that are similar to Arvinas include Elanco Animal Health, Viatris, Zai Lab, BioMarin Pharmaceutical, Dr. Reddy's Laboratories, Ono Pharmaceutical, Maravai LifeSciences, Grifols, Bausch Health Companies, CureVac, Jazz Pharmaceuticals, Teva Pharmaceutical Industries, BridgeBio Pharma, United Therapeutics and Biohaven Pharmaceutical.

How do I contact Arvinas' investor relations team?

Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected] The official website for Arvinas is www.arvinas.com.